Amrita Institute of Medical Sciences Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2006
NCT00299195
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Amrita Institute of medical sciences and research Center kochi | Amrita Institute of Medical Sciences, Kochi | Amrita Institute of Medical Sciences & Research Center | Amrita Institute of Sciences, AIMS, Cochin, India

Active Ingredients

Drugs in Phase 4 Trials (2)

insulin glargine (toujeo) (1 trial)

tranexamic acid (cyklokapron) (1 trial)

Drugs in Phase 3 Trials (1)

cisplatin (platinol) (1 trial)

Drugs in Phase 2 Trials (4)

arhalofenate (1 trial)

autologous mesenchymal stem cells (1 trial)

pioglitazone (actos) (1 trial)

sitagliptin (januvia) (1 trial)

Drugs in Phase 1 Trials (2)

branched chain amino acids (1 trial)

lactulose (cephulac) (1 trial)

Drugs in Other Trials (1)

sulindac (clinoril) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Diabetic Foot (Phase 4)

Foot Ulcer (Phase 4)

Ischemia (Phase 2)

Ulcer (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 10